Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
The Readout

Inside the Nant machine & the biotech IPO rides again 

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan April 14, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for April 14, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Combination of two drugs can help treat methamphetamine addiction…
Combination of two drugs can help treat methamphetamine addiction for some, new clinical trial data shows 
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
When a patient nears the end, a feared therapy…
When a patient nears the end, a feared therapy can also comfort
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories